drugset / Trial / NCT01176747

Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients

NCT01176747

Phase 1/2 Completed 28 enrolled Chiesi Farmaceutici S.p.A.
NaParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the lung deposition and distribution pattern of Beclometasone and Formoterol using a gamma-scintigraphic technique after inhalation of a single dose of 99mTc-radiolabelled BDP/formoterol fixed combination administered Via the NEXT DPI in healthy volunteers, asthmatic and COPD patients. Additionally, the systemic exposures to formoterol, BDP and its monopropionate metabolite (B17MP) will be investigated.

Timeline

Start
2010-08
Primary completion
2010-09
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Beclomethasone Small molecule 400 ug Inhaled
Subject Formoterol Other / unclassified 24 ug Inhaled